Dose of dendritic cells (APC8015) and soluble antigen (PA2024) delivered to patients
| Patient | Dendritic cells (CD54+; 106/m2)a | PA2024 (mg/dose) | ||
|---|---|---|---|---|
| Infusion no. 1 | Infusion no. 2 | |||
| 1–3 | 248 ± 86 | 306 ± 237 | 0.3 | |
| 4–6 | 230 ± 140 | 147 ± 49 | 0.6 | |
| 7–13b | 325 ± 155 | 217 ± 128 | 1.0 | |
a No difference among groups was statistically significant.
b Patient 7 received one dose of dendritic cells and no PA2024 because of early disease progression. Patients 5 and 8 received only one dose of PA2024, and patients 9 and 12 received only two doses.